Gsa Capital Partners LLP Rigel Pharmaceuticals Inc Transaction History

Gsa Capital Partners LLP

$1.32 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$1.12 - $1.57 $53,213 - $74,593	-47,512 Reduced 3.33%	1,379,530 $2.04 Million
Q4 2023 Feb 16, 2024	BUY	$0.72 - $1.56 $328,032 - $710,737	455,601 Added 46.9%	1,427,042 $2.07 Million
Q3 2023 Nov 15, 2023	BUY	$1.07 - $1.39 $655,712 - $851,812	612,815 Added 170.88%	971,441 $1.05 Million
Q2 2023 Aug 14, 2023	BUY	$1.12 - $1.82 $38,335 - $62,294	34,228 Added 10.55%	358,626 $462,000
Q1 2023 May 12, 2023	BUY	$1.25 - $2.0 $286,411 - $458,258	229,129 Added 240.51%	324,398 $428,000
Q4 2022 Feb 13, 2023	BUY	$0.67 - $11.9 $63,830 - $1.13 Million	95,269 New	95,269 $143,000
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $271,484 - $410,678	-115,036 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$3.5 - $4.5 $402,626 - $517,662	115,036 New	115,036 $418,000
Q2 2021 Aug 05, 2021	SELL	$3.09 - $4.54 $49,572 - $72,835	-16,043 Closed	0 $0
Q1 2021 May 10, 2021	BUY	$3.35 - $4.93 $53,744 - $79,091	16,043 New	16,043 $55,000
Q3 2020 Nov 06, 2020	SELL	$1.78 - $4.13 $150,283 - $348,691	-84,429 Closed	0 $0
Q2 2020 Aug 11, 2020	SELL	$1.41 - $2.05 $198,976 - $289,291	-141,118 Reduced 62.57%	84,429 $155,000
Q1 2020 May 12, 2020	SELL	$1.27 - $3.0 $25,323 - $59,820	-19,940 Reduced 8.12%	225,547 $352,000
Q4 2019 Feb 12, 2020	BUY	$1.6 - $2.43 $70,974 - $107,792	44,359 Added 22.06%	245,487 $525,000
Q3 2019 Nov 12, 2019	BUY	$1.63 - $2.62 $327,838 - $526,955	201,128 New	201,128 $376,000
Q4 2018 Feb 12, 2019	SELL	$2.08 - $3.36 $58,032 - $93,744	-27,900 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$2.6 - $3.59 $72,540 - $100,161	27,900 New	27,900 $90,000

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account